AU2014329421B2 - Stabilized efinaconazole compositions - Google Patents

Stabilized efinaconazole compositions Download PDF

Info

Publication number
AU2014329421B2
AU2014329421B2 AU2014329421A AU2014329421A AU2014329421B2 AU 2014329421 B2 AU2014329421 B2 AU 2014329421B2 AU 2014329421 A AU2014329421 A AU 2014329421A AU 2014329421 A AU2014329421 A AU 2014329421A AU 2014329421 B2 AU2014329421 B2 AU 2014329421B2
Authority
AU
Australia
Prior art keywords
composition
less
edta
amount
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014329421A
Other languages
English (en)
Other versions
AU2014329421A1 (en
Inventor
Varsha BHATT
Nayan Desai
Radhakrishnan Pillai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Dow Pharmaceutical Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52777446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014329421(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences Inc filed Critical Dow Pharmaceutical Sciences Inc
Publication of AU2014329421A1 publication Critical patent/AU2014329421A1/en
Application granted granted Critical
Publication of AU2014329421B2 publication Critical patent/AU2014329421B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2014329421A 2013-10-03 2014-10-02 Stabilized efinaconazole compositions Active AU2014329421B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886569P 2013-10-03 2013-10-03
US61/886,569 2013-10-03
US201461922867P 2014-01-01 2014-01-01
US61/922,867 2014-01-01
PCT/US2014/058911 WO2015051183A1 (en) 2013-10-03 2014-10-02 Stabilized efinaconazole compositions

Publications (2)

Publication Number Publication Date
AU2014329421A1 AU2014329421A1 (en) 2016-04-07
AU2014329421B2 true AU2014329421B2 (en) 2018-08-02

Family

ID=52777446

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014329421A Active AU2014329421B2 (en) 2013-10-03 2014-10-02 Stabilized efinaconazole compositions

Country Status (13)

Country Link
US (4) US9662394B2 (enExample)
EP (1) EP3052487B1 (enExample)
JP (3) JP6516759B2 (enExample)
KR (1) KR102320051B1 (enExample)
CN (2) CN105683184B (enExample)
AU (1) AU2014329421B2 (enExample)
CA (1) CA2924748C (enExample)
IL (1) IL244850B (enExample)
MX (1) MX363386B (enExample)
MY (1) MY179756A (enExample)
PH (1) PH12016500586B1 (enExample)
SG (1) SG11201602596UA (enExample)
WO (1) WO2015051183A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
CN105683184B (zh) 2013-10-03 2019-05-10 道尔医药科学公司 稳定的艾菲康唑组合物
CA2931144C (en) 2013-11-22 2020-02-04 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CN106918672B (zh) * 2015-12-28 2021-02-09 中美华世通生物医药科技(武汉)有限公司 利用hplc测定艾氟康唑原料药及其制剂中有关物质的方法
CN110087652A (zh) * 2016-12-16 2019-08-02 株式会社钟化 甲癣治疗剂
WO2019077163A2 (en) * 2017-10-20 2019-04-25 Galenicum Health S.L. PHARMACEUTICAL DEVICE
JP7430070B2 (ja) * 2019-02-08 2024-02-09 沢井製薬株式会社 エフィナコナゾール含有爪外用液
KR102060546B1 (ko) * 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
KR102352960B1 (ko) * 2019-06-07 2022-01-19 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
KR20210032672A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 에피나코나졸을 함유하는 안정화된 약학 조성물
WO2021054535A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054533A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054531A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 항산화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032665A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제 및 항산화제의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR102266145B1 (ko) 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
JP2021054781A (ja) 2019-09-26 2021-04-08 デボン エルエス,リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR20220119363A (ko) 2019-12-24 2022-08-29 가껭세이야꾸가부시기가이샤 에피나코나졸을 함유하는 의약
KR102394599B1 (ko) * 2020-03-19 2022-05-06 동아에스티 주식회사 에피나코나졸을 함유하는 국소 투여용 약학 조성물
WO2021245206A1 (en) 2020-06-03 2021-12-09 The Materia Company Limited Topical solution of efinaconazole with high subungual penetration
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
EP3981402A4 (en) * 2020-08-14 2022-08-10 BL&H Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF RINGWORM
KR102729906B1 (ko) * 2020-10-30 2024-11-14 주식회사 대웅제약 항진균제를 포함하는 안정화된 조성물
KR102301743B1 (ko) 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물
US20240108613A1 (en) * 2021-02-05 2024-04-04 Acp Laboratories Llc Topical composition for treating fungi forming on a user's body
KR102863832B1 (ko) * 2021-05-04 2025-09-25 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
WO2022235048A1 (ko) * 2021-05-04 2022-11-10 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
KR20230158920A (ko) 2022-05-12 2023-11-21 주식회사한국파마 에피나코나졸을 함유하는 안정화된 국소투여용 약학 조성물
KR102842759B1 (ko) 2022-05-20 2025-08-06 주식회사한국파마 항진균제로서 에피나코나졸을 함유하는 약학 조성물
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE41306C (de) A. STORIE VAN DEN ABEELE in Brügge, Belgien Tabak-Trockner
US3655290A (en) 1970-10-02 1972-04-11 Griffith & Associates Inc Applicator instrument
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
DE3106635A1 (de) 1981-02-23 1982-09-09 Bayer Ag Antimykotisches mittel mit hoher wirkstoff-freisetzung in form von stiften
US4384589A (en) 1981-07-27 1983-05-24 American Cyanamid Company Novel liquid delivery system for toiletries
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
JPS6234955A (ja) 1985-08-01 1987-02-14 ダウ コ−ニング コ−ポレ−ション 透明シリコ−ン組成物
AU599064B2 (en) 1985-11-04 1990-07-12 Dermatological Products Of Texas Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5208257A (en) * 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
JPS63188609A (ja) 1987-01-30 1988-08-04 Sansho Seiyaku Kk 着色を防止した外用剤
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5449715A (en) * 1991-09-17 1995-09-12 Isp Investments Inc. Colorless, non-toxic, stabilized aqueous solution of a C1-C5 alkyl vinyl ether and maleic acid copolymers
ES2091019T3 (es) 1992-02-12 1996-10-16 Janssen Cilag S P A Formulaciones liposomicas de itraconazol.
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
GB9308103D0 (en) 1993-04-20 1993-06-02 Unilever Plc Cosmetic composition
DE69407409T2 (de) 1993-05-10 1998-04-09 Kaken Pharma Co Ltd Azolylamin-derivat
US5916545A (en) 1993-07-28 1999-06-29 Pfizer Inc. Antifungal nail solution
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
ATE183926T1 (de) 1993-09-29 1999-09-15 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
JP3608209B2 (ja) 1993-10-27 2005-01-05 大正製薬株式会社 クロタミトン配合外用剤
FR2711898B1 (fr) 1993-11-05 1995-12-29 Oreal Pinceau pour appliquer du vernis à ongles, ou un produit analogue.
US6040266A (en) 1994-02-22 2000-03-21 Ultramet Foam catalyst support for exhaust purification
FR2717057B1 (fr) 1994-03-14 1996-04-12 Oreal Pinceau de vernis à ongles et ensemble d'application de vernis à ongles muni d'un tel pinceau.
US5487776A (en) 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
US6080393A (en) 1994-07-09 2000-06-27 Johnson & Johnson Consumer Products, Inc. Skin care composition comprising a retinoid
WO1996030011A1 (en) 1995-03-30 1996-10-03 Bioplex, L.C. Topical antimycotic compositions
US5549930A (en) 1995-05-25 1996-08-27 Reysis; Moisei Dryer and top coat for nail polish
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US5696105A (en) 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
US5874069A (en) 1997-01-24 1999-02-23 Colgate-Palmolive Company Cosmetic composition containing silicon-modified amides as thickening agents and method of forming same
JP4227677B2 (ja) 1996-12-10 2009-02-18 杏林製薬株式会社 被膜形成性抗真菌剤組成物
JP2001518879A (ja) 1997-03-31 2001-10-16 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 薬剤化合物の向上した浸透性のための溶媒システム
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6165484A (en) * 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6197305B1 (en) 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
KR100269323B1 (ko) 1998-01-16 2000-10-16 윤종용 반도체장치의백금막식각방법
US5997893A (en) 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
US20020022660A1 (en) 1998-01-20 2002-02-21 Hanuman B. Jampani Deep penetrating antimicrobial compositions
US6022551A (en) 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
US5972358A (en) 1998-01-20 1999-10-26 Ethicon, Inc. Low tack lotion, gels and creams
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
PL343559A1 (en) 1998-04-03 2001-08-27 Colgate Palmolive Co Improved low residue cosmetic composition
US6306375B1 (en) 1998-05-01 2001-10-23 The Procter & Gamble Company Long wear nail polish having defined surface properties
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6264927B1 (en) 1998-08-27 2001-07-24 Elmer P. Monahan Topical solution and method for the treatment of nail fungus
DE59911740D1 (de) 1998-09-10 2005-04-14 Bioequal Ag Muttenz Topisch anwendbare mittel gegen nagelpilzerkrankungen
US7026308B1 (en) 1999-06-25 2006-04-11 The Procter & Gamble Company Topical anti-microbial compositions
ATE434667T1 (de) 1999-07-28 2009-07-15 Kaken Pharma Co Ltd Verfahren zum nachweis pathogener mikroorganismen und antimikrobieller mittel, verfahren zum nachweis der arzneimittelwirkung antimikrobieller mittel und antimikrobielle mittel
AU5838700A (en) 1999-07-30 2001-02-19 Procter & Gamble Company, The Method for treating and preventing finger disorders
JP4780429B2 (ja) * 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
US6433073B1 (en) 2000-07-27 2002-08-13 3M Innovative Properties Company Polyurethane dispersion in alcohol-water system
US6676953B2 (en) 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030039621A1 (en) 2001-04-10 2003-02-27 L'oreal Two-coat make-up product, its use and a kit containing the make-up product
US6664292B2 (en) 2001-06-04 2003-12-16 Mark H. Bogart Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
US6821508B2 (en) 2001-06-27 2004-11-23 Rutgers, The State University Composition and method for topical nail treatment
WO2003013447A2 (en) 2001-08-07 2003-02-20 Dow Corning Corporation Hair and skin care compositions containing siloxane-based polyamide copolymers
US7043791B2 (en) 2001-10-16 2006-05-16 Aubex Corporation Applicator
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
JP2004083439A (ja) 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤
JP2005538156A (ja) 2002-09-05 2005-12-15 ガルデルマ・ソシエテ・アノニム 爪塗布用溶液
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US20050142094A1 (en) 2003-03-12 2005-06-30 Manoj Kumar Use of repeat sequence protein polymers in personal care compositions
US20040180025A1 (en) 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
EP1635770B1 (en) 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
GB2407496A (en) 2003-10-27 2005-05-04 Dow Corning Method for forming a polysiloxane film on a biological surface
MXPA06005587A (es) 2003-11-21 2006-08-11 Galderma Res & Dev Composicion rociable para administracion de derivados de vitamina d.
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
US7622844B1 (en) 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20050176650A1 (en) 2004-02-09 2005-08-11 Xanodyne Pharmacal, Inc. Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US20060008538A1 (en) 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US20070082039A1 (en) 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060165747A1 (en) 2005-01-24 2006-07-27 David Rolf Antifungal composition, method and kit for topically treating onychomycosis
KR101426220B1 (ko) 2005-02-16 2014-08-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
US20060280706A1 (en) 2005-05-25 2006-12-14 L'oreal Rinse-off cosmetic composition containing interference particles
US20070071705A1 (en) 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
CA2633489C (en) 2005-12-14 2013-09-24 Zars Pharma, Inc. Compositions and methods for treating dermatological conditions
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20070207107A1 (en) 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
BRPI0621386B8 (pt) 2006-03-08 2021-07-13 Nihon Nihyaku Co Ltd composição farmacêutica para o uso externo
US7950865B2 (en) 2006-03-21 2011-05-31 L'oreal Packaging and applicator device
JP5433881B2 (ja) 2006-04-03 2014-03-05 セヴァ アニマル ヘルス ピーティーワイ リミテッド 安定化ペントサンポリサルフェート(pps)製剤
WO2008001200A2 (en) 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
MXPA06008988A (es) 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
ES2350806T3 (es) * 2006-12-28 2011-01-27 Kaken Pharmaceutical Co., Ltd. Composición de gel para el tratamiento de micosis.
WO2008124131A1 (en) 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2009263346A (ja) 2008-03-31 2009-11-12 Kose Corp カイネチンを含有する乳化型化粧料
MX2011008204A (es) * 2009-02-05 2011-12-06 Targeted Delivery Technologies Ltd Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
ES2468540T3 (es) 2009-02-13 2014-06-16 Topica Pharmaceuticals, Inc Formulación antif�ngica
FR2942716B1 (fr) 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
EP2453874A2 (en) 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
WO2011045765A1 (en) * 2009-10-14 2011-04-21 Scuola Internazionale Superiore Di Studi Avanzati TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR
WO2011064558A2 (en) * 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
FR2954164B1 (fr) 2009-12-18 2012-03-16 Galderma Pharma Sa Composition antifongique destinee a etre appliquee sur l'ongle perfore
BR112012029418A2 (pt) * 2010-05-20 2017-02-21 Hyun Jung Chung composição de preparação para a pele para uso externo com excelentes efeitos antibacterianos e antifúngicos
EP3391890B1 (en) 2010-06-29 2021-08-25 Merck Sharp & Dohme Corp. Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
ES2556782T3 (es) * 2010-08-31 2016-01-20 Kaken Pharmaceutical Co., Ltd. Procedimiento para producir derivados de 1-triazol-2-butanol
JP6005344B2 (ja) 2011-07-05 2016-10-12 科研製薬株式会社 爪白癬薬用塗布具
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
CN105683184B (zh) 2013-10-03 2019-05-10 道尔医药科学公司 稳定的艾菲康唑组合物
CA2931144C (en) 2013-11-22 2020-02-04 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails

Also Published As

Publication number Publication date
IL244850B (en) 2020-04-30
CA2924748A1 (en) 2015-04-09
JP2019108388A (ja) 2019-07-04
JP2020169207A (ja) 2020-10-15
KR102320051B1 (ko) 2021-10-29
MX2016004168A (es) 2016-09-08
US20170326240A1 (en) 2017-11-16
WO2015051183A1 (en) 2015-04-09
US20150099785A1 (en) 2015-04-09
PH12016500586A1 (en) 2016-05-23
US20210205457A1 (en) 2021-07-08
US10342875B2 (en) 2019-07-09
PH12016500586B1 (en) 2020-02-21
JP2016532722A (ja) 2016-10-20
EP3052487A4 (en) 2017-05-03
CN105683184B (zh) 2019-05-10
EP3052487B1 (en) 2018-09-05
MY179756A (en) 2020-11-12
US10864274B2 (en) 2020-12-15
JP6516759B2 (ja) 2019-05-22
CN110433291A (zh) 2019-11-12
JP6774518B2 (ja) 2020-10-28
EP3052487A1 (en) 2016-08-10
CN110433291B (zh) 2023-04-28
AU2014329421A1 (en) 2016-04-07
CA2924748C (en) 2019-09-03
KR20160068812A (ko) 2016-06-15
US9662394B2 (en) 2017-05-30
MX363386B (es) 2019-03-20
SG11201602596UA (en) 2016-04-28
US12076404B2 (en) 2024-09-03
CN105683184A (zh) 2016-06-15
US20190358329A1 (en) 2019-11-28
IL244850A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
US12076404B2 (en) Stabilized efinaconazole compositions as antifungals
EP2191826B1 (en) Pharmaceutical composition
AU2006339842B2 (en) Pharmaceutical composition for external use
JP6503303B2 (ja) 真菌感染の処置のための医薬組成物
US8962673B2 (en) Use of melatonin for treating and/or preventing mucositis
EP2762139B1 (en) Anti-fungal agent
JP2022113148A (ja) エフィナコナゾール外用組成物
EP4268825A9 (en) Pharmaceutical composition for transdermal administration containing epinastine or salt thereof and containing sulfur-based antioxidant
JP5019724B2 (ja) 抗真菌医薬組成物
HK40016945A (en) Stabilized efinaconazole compositions
HK40016945B (zh) 稳定的艾菲康唑组合物
RU2457831C1 (ru) Противогрибковый гель для местного нанесения
KR20190107987A (ko) 우수한 안정성을 갖는 폴마콕시브 함유 주사액 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)